Sandra Wessman

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

Jikui Guan, Susanne Fransson, Joachim T. Siaw et al. · Molecular Case Studies · 2018 · 47 citations · Full text

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Fredrik Sundquist, Kleopatra Georgantzi, Kirsten Brunsvig Jarvis et al. · Frontiers in Pediatrics · 2022 · 26 citations · Full text

Diagnostic Yield From a Nationwide Implementation of Precision Medicine for all Children With Cancer

Elisabeth Wadensten, Sandra Wessman, Frida Abel et al. · JCO Precision Oncology · 2023 · 26 citations · Full text

A complex DICER1 syndrome phenotype associated with a germline pathogenic variant affecting the RNase IIIa domain of DICER1

Emeli Pontén, Sofia Frisk, Fulya Taylan et al. · Journal of Medical Genetics · 2020 · 16 citations · Full text

Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation

Diana Treis, Ganesh Umapathy, Susanne Fransson et al. · JCO Precision Oncology · 2022 · 16 citations · Full text

Tumoral Pathology, Germline Alkal2 Variant, Medicine +6